
AI Digest · FDA approval of Verve's VERVE-102 gene editing drug by 2031 loses ground
Kalshi traders favor the FDA approving VERVE-102 before 2031, though that view lost ground this month. VERVE-102 is a one-time gene editing treatment from Verve Therapeutics, meant to lower cholesterol. The view was unchanged over the last week. The treatment is still experimental and edits a liver gene tied to cholesterol. Approval requires the FDA to review trial results and issue an approval letter. Progress in human trials decides how traders see it.